BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kontana A, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2019; 25(28): 3664-3668 [PMID: 31391764 DOI: 10.3748/wjg.v25.i28.3664]
URL: https://www.wjgnet.com/1007-9327/full/v25/i28/3664.htm
Number Citing Articles
1
Kavita Garg, Trenton Reinicke, Satish K. Garg. NAFLD and NASH and DiabetesDiabetes Technology & Therapeutics 2021; 23(S2): S-198 doi: 10.1089/dia.2021.2515
2
Mario Simental-Mendía, Adriana Sánchez-García, Mariana Rodríguez-Ramírez, Luis E. Simental-Mendía. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trialsPharmacological Research 2021; 163: 105319 doi: 10.1016/j.phrs.2020.105319
3
Tiantian Song, Shuchun Chen, Hang Zhao, Fei Wang, Huan Song, Dongliang Tian, Qiwen Yang, Licui Qi. Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver diseaseHepatology Research 2021; 51(6): 641 doi: 10.1111/hepr.13645
4
Meng Yang, Chang-An Geng, Xinguang Liu, Min Guan. Lipid Disorders in NAFLD and Chronic Kidney DiseaseBiomedicines 2021; 9(10): 1405 doi: 10.3390/biomedicines9101405